Resources from the same session
Prospective monitoring of lung function tests with CO and NO diffusion during high dose thoracic radiotherapy for lung cancer: The CONORT study
Presenter: Francoise Mornex
Session: Thoracic cancers
Resources:
Abstract
Prognostic significance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Presenter: Norikazu Matsuo
Session: Thoracic cancers
Resources:
Abstract
Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)
Presenter: Leora Horn
Session: Thoracic cancers
Resources:
Abstract
Phase 1b study of the safety and antitumour activity of durvalumab (MEDI4736) + tremelimumab in advanced NSCLC
Presenter: Naiyer Rizvi
Session: Thoracic cancers
Local diagnostic practices for advanced non-small-cell lung cancer (NSCLC) in Chinese Patients: subset of the IGNITE study
Presenter: Baohui Han
Session: Thoracic cancers
Resources:
Abstract
Invited discussant abstracts 421PD, 422PD, 423PD and 424PD
Presenter: Egbert Smit
Session: Thoracic cancers
Invited discussant abstracts 419O and 420O
Presenter: Daniel Tan
Session: Thoracic cancers
Invited discussant abstracts 417O and 418O
Presenter: Johan Vansteenkiste
Session: Thoracic cancers
Individualization of docetaxel (DTX) treatment in East-Asian advanced non-small cell lung cancer (NSCLC) patients based on pharmacokinetically (PK)-guided dosing strategy: an open-label randomized clinical trial
Presenter: Yuxiang Ma
Session: Thoracic cancers
Resources:
Abstract
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced non-squamous non–small-cell lung cancer (NSCLC) with activating EGFR mutation (mt): JO25567 exploratory subgroup analysis
Presenter: Yukio Hosomi
Session: Thoracic cancers
Resources:
Abstract